News
ALDX
--
0.00%
--
Aldeyra Therapeutics to Participate in the Virtual Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer of Aldeyra, will participate in a fireside conversation with Justin Kim, Executive Director, Biotech Equity Research...
Business Wire · 09/09 12:00
Aldeyra Therapeutics to Participate in Upcoming Virtual Investor Conferences
LEXINGTON, Mass., September 02, 2021--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company developing novel immune-modulating therapies to treat ocular and systemic diseases, today announced that Todd C. Brady, M.D., Ph.D., Presiden...
Business Wire · 09/02 12:00
Altium Capital Management LP Buys Xtant Medical Holdings Inc, Kaleyra Inc, CTI BioPharma Corp, ...
GuruFocus News · 08/17 18:38
EAM Investors, LLC Buys Everi Holdings Inc, PAVmed Inc, iHeartMedia Inc, Sells Atkore Inc, ...
GuruFocus News · 08/16 15:38
What Kind Of Investors Own Most Of Aldeyra Therapeutics, Inc. (NASDAQ:ALDX)?
If you want to know who really controls Aldeyra Therapeutics, Inc. ( NASDAQ:ALDX ), then you'll have to look at the...
Simply Wall St. · 08/07 07:24
The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Aug. 4)
Benzinga · 08/05 12:04
Aldeyra Therapeutics Reports Second-Quarter 2021 Financial Results and Recent Corporate Highlights
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company developing novel immune-modulating therapies to treat ocular and systemic diseases, today reported financial results for the quarter ended June 30, 2021 and recent corporate highl...
Business Wire · 08/05 11:00
-- Earnings Flash (ALDX) ALDEYRA THERAPEUTICS Reports Q2 Loss $-0.28
MT Newswires · 08/05 07:28
Aldeyra Secures US Orphan Drug Tag For Its Retinitis Pigmentosa Candidate
Benzinga · 08/04 15:23
BRIEF-Aldeyra Therapeutics Receives Orphan Drug Designation From FDA For ADX-2191 To Treat Retinitis Pigmentosa
reuters.com · 08/04 12:24
Aldeyra Therapeutics shares rise after FDA orphan drug status for ADX-2191
Aldeyra Therapeutics (NASDAQ:ALDX) announces that the U.S. FDA has granted orphan drug designation for ADX-2191 (methotrexate for intravitreal injection) for the treatment of retinitis pigmentosa (RP), a group of rare genetic eye diseases.
Seekingalpha · 08/04 12:22
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
 
Benzinga · 08/04 12:07
Aldeyra Therapeutics Receives Orphan Drug Designation from the U.S. Food and Drug Administration for ADX-2191 to Treat Retinitis Pigmentosa
Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for ADX-2191 (methotrexate for intravitreal injection) for the treatment of retinitis pigmentosa (RP). ...
Business Wire · 08/04 12:00
The Week Ahead In Biotech (Aug. 1-7): Biopharma Earnings Pick Up Pace, Eton Awaits FDA Decision, Focus On Pending Clinical Readouts and IPOs
Biotech stocks showed a lack of direction in the week ending July 30 amid earnings releases from big pharma companies.
Benzinga · 08/01 14:13
Is Aldeyra Therapeutics Inc (ALDX) A Good Stock To Buy?
A whopping number of 13F filings filed with U.S. Securities and Exchange Commission has been processed by Insider Monkey so that individual investors can look at the overall hedge fund sentiment towards the stocks included in their watchlists. These freshl...
Insider Monkey · 07/29 19:53
Aldeyra Therapeutics Schedules Webcast and Conference Call to Report Second-Quarter 2021 Financial Results and Discuss Recent Business Highlights
LEXINGTON, Mass., July 29, 2021--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) will host a conference call at 8:00 a.m. ET Thursday, August 5, 2021 to report financial results for the quarter ended June 30, 2021 and discuss recent business highlights...
Business Wire · 07/29 12:00
Aldeyra's (ALDX) ADX-2191 Gets Orphan Drug Tag for Rare Cancer
The FDA grants an Orphan Drug designation to Aldeyra's (ALDX) ADX-2191 for the treatment of primary vitreoretinal lymphoma.
Zacks · 07/21 15:13
Aldeyra Stock Trading Higher On FDA Orphan Drug Tag For Primary Vitreoretinal Lymphoma Candidate
Benzinga · 07/20 13:19
BRIEF-Aldeyra Therapeutics Receives Orphan Drug Designation From The U.S. Food And Drug Administration For ADX-2191 To Treat Primary Vitreoretinal Lymphoma
reuters.com · 07/20 12:56
Webull provides a variety of real-time ALDX stock news. You can receive the latest news about Aldeyra through multiple platforms. This information may help you make smarter investment decisions.
About ALDX
Aldeyra Therapeutics, Inc., formerly Aldexa Therapeutics, Inc., is a biotechnology company. The Company's principal activities include raising capital and research and development activities. The Company's segment is the identification and development of a treatment for diseases related to high levels of aldehydes. The Company is focused on the development of products for diseases caused by inflammation and inborn errors of metabolism that are caused by naturally occurring toxic and pro-inflammatory chemical species known as aldehydes. The Company has developed a series of aldehyde traps, molecules that are designed to sequester and allow for the degradation of aldehydes. The Company's aldehyde trap, NS2, is a product candidate that is under development for the treatment of allergic conjunctivitis and related rare allergic ocular diseases, noninfectious anterior uveitis, sjogren-larsson syndrome (SLS) and succinic semi-aldehyde dehydrogenase deficiency.